SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-13.21%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$624M
AUM Growth
+$624M
(-3.7%)
Cap. Flow
+$58.5M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
44.27%
Holding
87
New
22
Increased
22
Reduced
22
Closed
15
Top Buys
| 1 |
The Beauty Health Co
SKIN
|
$39.2M |
| 2 |
Organogenesis Holdings
ORGO
|
$13.4M |
| 3 |
AnaptysBio
ANAB
|
$13.1M |
| 4 |
CVS Health
CVS
|
$11.8M |
| 5 |
Tandem Diabetes Care
TNDM
|
$10.9M |
Top Sells
| 1 |
Illumina
ILMN
|
$21.8M |
| 2 |
OraSure Technologies
OSUR
|
$20.7M |
| 3 |
Hologic
HOLX
|
$17.3M |
| 4 |
Smith & Nephew
SNN
|
$12.3M |
| 5 |
Lantheus
LNTH
|
$8.13M |
Sector Composition
| 1 | Healthcare | 89.55% |
| 2 | Consumer Staples | 6.75% |
| 3 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Penumbra
PEN
$10.5B
| $8.57M | 1.34% |
+68,800
| New | +$8.57M |
|
27
Vaxcyte
PCVX
$4.17B
| $8.07M | 1.26% |
370,650
+42,300
| +13% | +$920K |
|
28
Iovance Biotherapeutics
IOVA
$800M
| $7.94M | 1.24% |
+719,600
| New | +$7.94M |
|
|
PVLA
29
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $7.73M | 1.21% |
4,134,868
| – | – |
|
30
Steris
STE
$23.9B
| $7.69M | 1.2% |
37,310
-3,950
| -10% | -$814K |
|
31
Supernus Pharmaceuticals
SUPN
$2.52B
| $7.46M | 1.16% |
258,100
+7,100
| +3% | +$205K |
|
32
CVRx
CVRX
$204M
| $6.37M | 0.99% |
1,059,040
+96,875
| +10% | +$582K |
|
|
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.21M | 0.97% |
+77,842
| New | +$6.21M |
|
34
Incyte
INCY
$17B
| $6.06M | 0.94% |
+79,700
| New | +$6.06M |
|
35
Transmedics
TMDX
$3.65B
| $5.8M | 0.91% |
+184,455
| New | +$5.8M |
|
|
EIGR
36
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $5.33M | 0.83% |
846,000
+63,000
| +8% | +$397K |
|
37
STAAR Surgical
STAA
$1.35B
| $5.33M | 0.83% |
+75,094
| New | +$5.33M |
|
|
NARI
38
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $4.92M | 0.77% |
+72,298
| New | +$4.92M |
|
39
Fate Therapeutics
FATE
$115M
| $4.82M | 0.75% |
194,400
-11,500
| -6% | -$285K |
|
40
Enanta Pharmaceuticals
ENTA
$189M
| $4.73M | 0.74% |
100,000
-102,485
| -51% | -$4.84M |
|
41
Exact Sciences
EXAS
$9.33B
| $4.69M | 0.73% |
+119,000
| New | +$4.69M |
|
42
Natera
NTRA
$23B
| $4.67M | 0.73% |
131,873
-23,127
| -15% | -$820K |
|
43
Rocket Pharmaceuticals
RCKT
$358M
| $4.38M | 0.68% |
+318,100
| New | +$4.38M |
|
44
Establishment Labs
ESTA
$1.11B
| $4.26M | 0.67% |
+78,400
| New | +$4.26M |
|
45
InMode
INMD
$917M
| $4.2M | 0.66% |
187,449
+40,949
| +28% | +$918K |
|
46
Pliant Therapeutics
PLRX
$105M
| $3.93M | 0.61% |
490,000
+250,000
| +104% | +$2M |
|
|
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
| $3.83M | 0.6% |
+154,400
| New | +$3.83M |
|
48
Mirum Pharmaceuticals
MIRM
$3.75B
| $3.82M | 0.6% |
196,018
-147,482
| -43% | -$2.87M |
|
49
Celcuity
CELC
$2.3B
| $3.81M | 0.59% |
418,912
+386,839
| +1,206% | +$3.52M |
|
|
50
Lantheus
LNTH
$3.75B
| $3.65M | 0.57% |
55,222
-123,205
| -69% | -$8.13M |
|